Everolimus Effective in Treating Neuroendocrine Tumors


Everolimus improved progression-free survival by 6 to 8 months compared with placebo in patients with advanced neuroendocrine tumors of the gastrointestinal tract.

A subgroup analysis from the phase III RADIANT-4 trial found that the mTOR inhibitor everolimus improved progression-free survival by 6 to 8 months compared with placebo in patients with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract. These results will be presented at the 2016 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 21–23 in San Francisco (abstract 315).

“In my opinion, in advanced NET patients, everolimus is an effective and new and exciting treatment option in a disease where there are few treatments to date,” said study author Simron Singh, MD, MPH, a medical oncologist at the Sunnybrook Odette Cancer Centre in Toronto, at a presscast ahead of the meeting.

The RADIANT-4 trial randomized 302 patients with advanced, progressive NETs 2:1 to either 10 mg everolimus daily or placebo. While RADIANT-4 also included patients with disease that originated in the lungs, the current analysis included patients with NETs of the gastrointestinal tract (n = 175) as well as NETs of unknown primary origin (n = 36).

The analysis found that patients with gastrointestinal NETs had a median progression-free survival of 13.1 months in the everolimus arm compared with 5.4 months in the placebo arm, with an estimated 44% risk reduction in disease progression. The most common site of NET origin was the ileum (41% of patients) followed by the rectum (23% of patients).

In patients who had NETs with an unknown primary origin, the median progression-free survival was 13.6 months in the everolimus arm compared with 7.5 months in the placebo arm, with an estimated 40% risk reduction in progression of disease.

“What was interesting in this study is that regardless of prior treatment, patients appeared to benefit from everolimus across the board,” said Singh.

All patients had disease progression following surgery, chemotherapy, or treatment with a somatostatin analog. Seventy percent of patients with gastrointestinal-originating NETs had undergone surgery, 59% had received somatostatin, and 19% had received prior chemotherapy.

Everolimus is an oral drug currently approved by the US Food and Drug Administration for the treatment of metastatic estrogen receptor–positive breast cancer, pancreatic cancer, renal cell carcinoma, and adults and children with subependymal giant cell astrocytoma.

The most common high-grade adverse events reported in more than 5% patients in the subgroup were diarrhea, hypertension, stomatitis, abdominal pain, fatigue, and acute renal failure. The adverse event profile was consistent with prior studies of everolimus with no new safety signals uncovered.

The study was funded by Novartis Pharmaceuticals.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content